Preliminary comparative considerations about urinary cytology and the Bard BTA test in the diagnosis and follow-up of superficial bladder cancer

1995 ◽  
Vol 62 (1_suppl) ◽  
pp. 88-90
Author(s):  
C. Boccafoschi ◽  
F. Montefiore ◽  
S. Treffiletti ◽  
D. Signorello ◽  
A. Langé
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Bladder Tumour ◽  
Transitional Cell ◽  
Latex Agglutination ◽  
Urinary Cytology ◽  
In Vitro Test ◽  
Carcinoma Of The Bladder

— The value of urinary cytology in the diagnosis and follow-up of superficial transitional cell carcinoma of the bladder is well known. Results of traditional cytologic examinations may be affected by the different methods of urine collection, preservation, manipulation and observation of the samples so that more objective tools are desirable. The aim of this study in to compare the traditional cytologic examinations with a new diagnostic in-vitro test (Bard BTA test), which can detect antigen complexes in the urine due to the contact of the tumour cells with the basement membrane. The Bard BTA test is a latex agglutination assay which identifies the bladder tumour antigens in the urine. The result of the agglutination reaction (positive or negative) may be visually distinguished by the variation in colour of special strips of testing paper. The Authors report on a preliminary experience in the follow-up of patients with previous superficial transitional cell carcinoma of the bladder: they compare the results of traditional cytology, the Bard BTA test and cystoscopy and have found agreement in 70% of the cases.

Detection of Recurrent Transitional Cell Carcinoma of the Bladder with Nuclear Matrix Protein-22 in a Follow-up Setting

UroOncology ◽  
2003 ◽  
Vol 2 (3) ◽  
pp. 137-142
Author(s):  
J.W.A. Oosterhuis ◽  
R.P.E. Pauwels ◽  
R.F.M. Schapers ◽  
J. van Pelt ◽  
W. Smeets ◽  
...  
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Nuclear Matrix ◽  
Matrix Protein ◽  
Transitional Cell ◽  
Nuclear Matrix Protein ◽  
Carcinoma Of The Bladder

Clinical evaluation of nuclear matrix protein 22 as urinary marker of transitional cell carcinoma of bladder

2008 ◽  
Vol 75 (1) ◽  
pp. 20-23
Author(s):  
R.F. Liotta ◽  
F. Mangiapia ◽  
M.L. Tarantino ◽  
S. Di Meo ◽  
V. Mirone ◽  
...  
Keyword(s):  
Transitional Cell Carcinoma ◽  
Tumor Marker ◽  
Cell Carcinoma ◽  
Nuclear Matrix ◽  
Matrix Protein ◽  
Transitional Cell ◽  
Cancer Surveillance ◽  
Urinary Cytology ◽  
Nuclear Matrix Protein

Objectives. Biomarkers (BTA, NMP22, FDP etc.) have been and continue to be evaluated as adjuncts or substitutes for cystoscopy, which is invasive and uncomfortable for some patients. Nuclear matrix protein-22 (NMP22) is involved in the regulation of nuclear processes. The main objective of the present study is to evaluate the clinical utility of urinary NMP22 as a tumor marker in the follow-up of transitional cell carcinoma (TCC) of the bladder. Materials and Methods. The study included 62 patients undergoing follow-up, who had had TCC of bladder but who were disease-free at the beginning of the study, as confirmed by cystoscopy. Urine samples were collected for urinary cytology and NMP22 test before the cystoscopy. All samples were processed according to the instructions provided with the manufacturer's kit instructions. Results. 12 cases of TCC recurrences were detected with biopsy. Cystoscopy was positive in 8 cases, NMP22 test was positive in 11 cases, and in only one case the cytopathology yielded positive results. In 14 cases NMP22 resulted as false positive. Conclusions. Urinary NMP22 appeared to be a potential tumor marker for detecting TCC of the bladder, which might rise the sensitivity of cystoscopy especially in high-grade cancer surveillance more than cytology might do.

Transitional cell carcinoma of the upper urinary tract: Follow-up and prognostic factors

1996 ◽  
Vol 63 (1) ◽  
pp. 50-54
Author(s):  
F. Pagano ◽  
A. Tasca ◽  
C.A. Levorato
Keyword(s):  
Overall Survival ◽  
Multivariate Analysis ◽  
Survival Rate ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Univariate Analysis ◽  
Bladder Tumour ◽  
Transitional Cell ◽  
Overall Survival Rate

— Of the 176 patients treated in our Institute over the last 16 years for upper tract transitional cell carcinoma (UTTCC), 155 were included in this study, 97 of whom had undergone nephroureterectomy, 28 conservative surgery and 30 endourologic treatment. The overall survival rate at 5 and 10 years was 73% and 58%, respectively. Univariate analysis of overall survival rate (O.S.) and disease-free survival rate (D.F.S.) showed no difference between patients with superficial and with invasive tumours, while multivariate analysis highlighted a difference. No difference was evident upon univariate and multivariate analysis of the patients with superficial tumours who underwent conservative (19) vs. radical (45) surgery. The same can be said for the so-called good prognosis tumours (pTa-T1-G2) and poor prognosis tumours (pT1-G3, pT2-4, G2-3) submitted to radical surgery. Overall survival was better in patients with no recurrent tumours compared to those with recurrences; furthermore prognosis was worse for patients with more than 2 recurrences. Tumour site, mono or multifocality and associated bladder tumour did not influence prognosis. Our experience confirms the basic importance of grade as a prognostic factor for UTTCC and the favourable prognosis for patients with superficial tumours, regardless of surgical technique. A rigid follow-up is mandatory for patients with more than 2 recurrences.

Sign in / Sign up

Export Citation Format

Share Document